Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma

Zolbetuximab is a chimeric monoclonal antibody that targets claudin‐18.2, a candidate biomarker in patients with advanced gastric/gastroesophageal cancer. This nonrandomized phase 1 study (NCT03528629) enrolled previously treated Japanese patients with claudin‐18.2–positive locally advanced/metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Kawazoe, Akihito, Hirakawa, Akihiro, Nakanishi, Yuka, Furuki, Satomi, Fukuda, Musashi, Ueno, Yoko, Raizer, Jeffrey, Arozullah, Ahsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067400/
https://www.ncbi.nlm.nih.gov/pubmed/36478334
http://dx.doi.org/10.1111/cas.15684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067400/
https://www.ncbi.nlm.nih.gov/pubmed/36478334
http://dx.doi.org/10.1111/cas.15684

Ejemplares similares